Hypertension - Pipeline Review, H2 2017

  • ID: 4438383
  • Drug Pipelines
  • 590 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Capricor Therapeutics Inc
  • Esperion Therapeutics Inc
  • Johnson & Johnson
  • Novartis AG
  • Savara Inc
  • MORE
Hypertension - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2017, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 40, 33, 31, 1, 87, 13 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 10 molecules, respectively.

Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • A1M Pharma AB
  • Capricor Therapeutics Inc
  • Esperion Therapeutics Inc
  • Johnson & Johnson
  • Novartis AG
  • Savara Inc
  • MORE
Introduction

Hypertension - Overview

Hypertension - Therapeutics Development

Hypertension - Therapeutics Assessment

Hypertension - Companies Involved in Therapeutics Development

Hypertension - Drug Profiles

Hypertension - Dormant Projects

Hypertension - Discontinued Products

Hypertension - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Hypertension, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Companies, H2 2017 (Contd..3), H2

Number of Products under Development by Companies, H2 2017 (Contd..4), H2

Number of Products under Development by Companies, H2 2017 (Contd..5), H2

Number of Products under Development by Companies, H2 2017 (Contd..6), H2

Number of Products under Development by Companies, H2 2017 (Contd..7), H2

Number of Products under Development by Universities/Institutes, H2

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Companies, H2 2017 (Contd..4), H2

Products under Development by Companies, H2 2017 (Contd..5), H2

Products under Development by Companies, H2 2017 (Contd..6), H2

Products under Development by Companies, H2 2017 (Contd..7), H2

Products under Development by Companies, H2 2017 (Contd..8), H2

Products under Development by Companies, H2 2017 (Contd..9), H2

Products under Development by Companies, H2 2017 (Contd..10), H2

Products under Development by Companies, H2 2017 (Contd..11), H2

Products under Development by Companies, H2 2017 (Contd..12), H2

Products under Development by Universities/Institutes, H2

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Target, H2 2017 (Contd..2), H2

Number of Products by Stage and Target, H2 2017 (Contd..3), H2

Number of Products by Stage and Target, H2 2017 (Contd..4), H2

Number of Products by Stage and Target, H2 2017 (Contd..5), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Hypertension - Pipeline by A1M Pharma AB, H2

Hypertension - Pipeline by Acceleron Pharma Inc, H2

Hypertension - Pipeline by Ache Laboratorios Farmaceuticos SA, H2

Hypertension - Pipeline by Actelion Pharmaceuticals Ltd, H2

Hypertension - Pipeline by Aerogen Ltd, H2

Hypertension - Pipeline by AnGes MG Inc, H2

Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2

Hypertension - Pipeline by Ascendis Pharma A/S, H2

Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2

Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2

Hypertension - Pipeline by Bayer AG, H2

Hypertension - Pipeline by Bial - Portela & Ca SA, H2

Hypertension - Pipeline by Biogen Inc, H2

Hypertension - Pipeline by Biolab Farmaceutica Ltda, H2

Hypertension - Pipeline by BioRestorative Therapies Inc, H2

Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H2

Hypertension - Pipeline by Bristol-Myers Squibb Co, H2

Hypertension - Pipeline by Camurus AB, H2

Hypertension - Pipeline by Capricor Therapeutics Inc, H2

Hypertension - Pipeline by Celsion Corp, H2

Hypertension - Pipeline by Celtaxsys Inc, H2

Hypertension - Pipeline by Cereno Scientific AB, H2

Hypertension - Pipeline by Chiesi Farmaceutici SpA, H2

Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2

Hypertension - Pipeline by Chugai Pharmaceutical Co Ltd, H2

Hypertension - Pipeline by CJ HealthCare Corp, H2

Hypertension - Pipeline by Complexa Inc, H2

Hypertension - Pipeline by Corion Biotech Srl, H2

Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H2

Hypertension - Pipeline by D. Western Therapeutics Institute Inc, H2

Hypertension - Pipeline by Daewon Pharm Co Ltd, H2

Hypertension - Pipeline by Daewoong Co Ltd, H2

Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H2

Hypertension - Pipeline by Daiichi Sankyo Co Ltd, H2

List of Figures

Number of Products under Development for Hypertension, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Top 10 Routes of Administration, H2

Number of Products by Stage and Top 10 Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • A1M Pharma AB
  • Acceleron Pharma Inc
  • Ache Laboratorios Farmaceuticos SA
  • Actelion Pharmaceuticals Ltd
  • Aerogen Ltd
  • AnGes MG Inc
  • Arena Pharmaceuticals Inc
  • Ascendis Pharma A/S
  • Asklepion Pharmaceuticals LLC
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • Bial - Portela & Ca SA
  • Biogen Inc
  • Biolab Farmaceutica Ltda
  • BioRestorative Therapies Inc
  • Boryung Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • Camurus AB
  • Capricor Therapeutics Inc
  • Celsion Corp
  • Celtaxsys Inc
  • Cereno Scientific AB
  • Chiesi Farmaceutici SpA
  • Chong Kun Dang Pharmaceutical Corp
  • Chugai Pharmaceutical Co Ltd
  • CJ HealthCare Corp
  • Complexa Inc
  • Corion Biotech Srl
  • Cumberland Pharmaceuticals Inc
  • D. Western Therapeutics Institute Inc
  • Daewon Pharm Co Ltd
  • Daewoong Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Daiichi Sankyo Co Ltd
  • DiaMedica Therapeutics Inc
  • Egalet Corp
  • Eli Lilly and Co
  • Esperion Therapeutics Inc
  • Galectin Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • HanAll Biopharma Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • HitGen LTD
  • Idorsia Ltd
  • Ildong Pharmaceutical Co Ltd
  • Innopharmax Inc
  • Insmed Inc
  • Insys Therapeutics Inc
  • Ionis Pharmaceuticals Inc
  • Ironwood Pharmaceuticals Inc
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • JW Pharmaceutical Corp
  • Leading BioSciences Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Les Laboratoires Servier SAS
  • LinXis BV
  • Liquidia Technologies Inc
  • Lotus Pharmaceutical Co Ltd
  • MannKind Corp
  • Marina Biotech Inc
  • Merck & Co Inc
  • Mezzion Pharma Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • N4 Pharma Plc
  • Nanoform Cardiovascular Therapeutics Ltd
  • Neurim Pharmaceuticals Ltd
  • Nippon Kayaku Co Ltd
  • Nippon Shinyaku Co Ltd
  • Nissan Chemical Industries Ltd
  • Northern Therapeutics Inc
  • Novartis AG
  • Omeros Corp
  • Peloton Therapeutics Inc
  • Pfizer Inc
  • PhaseBio Pharmaceuticals Inc
  • Pluristem Therapeutics Inc
  • Pulmokine Inc
  • Quantum Genomics SA
  • Reata Pharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • Relypsa Inc
  • Renova Therapeutics Inc
  • Respira Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • rEVO Biologics Inc
  • Rottapharm Biotech Srl
  • Sanofi
  • Sarfez Pharmaceuticals Inc
  • Savara Inc
  • Serodus ASA
  • Shanghai Pharmaceutical Co Ltd
  • SteadyMed Therapeutics Inc
  • Suda Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Takeda Pharmaceutical Co Ltd
  • Target Medicals LLC
  • The Medicines Company
  • Theravance Biopharma Inc
  • Toray Industries Inc
  • Torrent Pharmaceuticals Ltd
  • United Therapeutics Corp
  • Vascular BioSciences
  • Vectura Group Plc
  • VG Life Sciences Inc
  • Vicore Pharma AB
  • Vivus Inc
  • XORTX Pharma Corp
  • XuanZhu Pharma Co Ltd
  • Yuhan Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll